# A Study to Assess Safety and Efficacy of PRL3-Zumab in Patients With Solid Tumors

Source: https://onco.cc/trials/nct04452955/  
OnCo record `nct04452955` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of PRL3-zumab in advanced solid tumours, run by Intra-IMMUSG Pte Ltd, active and no longer recruiting.

## Summary

A Study to Assess Safety and Efficacy of PRL3-Zumab in Patients With Solid Tumors is a phase 2 interventional study registered as NCT04452955 by Intra-IMMUSG Pte Ltd, with 51 participants enrolled, started 2020-12-12 and due to reach its primary completion in 2026-12-01. Interventions recorded: PRL3-zumab.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04452955
- Phase: 2
- Setting: An Open Label, Multicenter, Safety and Efficacy Phase 2 Study of PRL3-Zumab in Solid Tumors
- Sponsor: Intra-IMMUSG Pte Ltd
- Enrolled: 51

## Sources

- ClinicalTrials.gov NCT04452955: https://clinicaltrials.gov/study/NCT04452955

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Intra-IMMUSG](https://onco.cc/companies/intra-immusg/), [Parexel](https://onco.cc/companies/parexel/)

---
JSON: https://onco.cc/api/v1/entities/nct04452955.json